PulseSight Therapeutics

Executive Summary

PulseSight Therapeutics is a clinical-stage biotechnology company headquartered in Paris, France, pioneering non-viral gene therapies for major ophthalmologic indications. Founded in 2016, the company's core focus is on age-related macular degeneration (AMD), including both geographic atrophy (dry AMD) and wet AMD. PulseSight's platform leverages a proprietary non-viral vector technology designed to enable safe, efficient, and durable delivery of therapeutic genes to retinal cells, addressing the limitations of viral vectors such as immunogenicity and limited payload capacity. The company's lead candidate targets the complement pathway for dry AMD and anti-angiogenic factors for wet AMD, potentially offering a one-time treatment alternative to chronic injections. With no approved gene therapies for AMD to date, PulseSight aims to fill a critical unmet need in this growing market. Currently in Phase 1 clinical development, PulseSight is advancing its lead program toward initial proof-of-concept data. The company operates in a competitive landscape with several gene therapy and small molecule approaches in development, but its non-viral differentiation could provide advantages in safety and manufacturing scalability. While still early-stage and without disclosed financial backing, PulseSight's science is supported by strong preclinical data and a clear regulatory pathway. Key upcoming catalysts include initial Phase 1 safety and biodata readouts, which will be pivotal for validating the platform and attracting partnerships. The company's long-term success hinges on demonstrating durable efficacy and a favorable safety profile in patients.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 interim safety and tolerability data for lead program in geographic atrophy40% success
• Q4 2026Phase 1 initial efficacy biomarker readout in wet AMD35% success
• H2 2026Potential strategic partnership or licensing deal for non-viral platform30% success